Project Details
Description
Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor positive
Status | Active |
---|---|
Effective start/end date | 9/1/24 → 8/31/27 |
Funding
- THE UNIVERSITY OF ALABAMA
- IMMUNOGEN, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.